With enhancements and continued patient focus, expedited regulatory pathways still delivering, EMA official says

Leading regulatory bodies around the world have various pathways in place to speed up the approval process for promising medicines that offer a solution to unmet medical needs.

The European Medicines Agency (EMA) is no exception, and its schemes are subject to regular review to see how well each is performing, according to Michael Berntgen, head of the Scientific Evidence Generation Department.

Dr Berntgen explained the objectives of these schemes during an interview with The Pharma Letter at last week’s European Health Forum Gastein meeting in Austria.